General Information of Drug (ID: DM4VAOG)

Drug Name
Gadobenate dimeglumine Drug Info
Synonyms
Hydron; Multihance; Gadobenate Dimeglumine [USAN]; Gadobenic acid; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance Multipack; B 1903617; E-7155; Gadobenate dimeglumine (USAN); Gd-BOPTA; Meglumine gadobenate (JAN); Multihance (TN); B-19036/7; Gadolinium(3+); Gd-Bopta/dimeg; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1] , [2] , [3]
Therapeutic Class
Contrast Media
Cross-matching ID
PubChem CID
6918204
CAS Number
CAS 127000-20-8
TTD Drug ID
DM4VAOG
VARIDT Drug ID
DR01257

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serum albumin (ALB) TTFNGC9 ALBU_HUMAN Binder [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID Highest Status REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Approved [5]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Approved [5]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Approved [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Serum albumin (ALB) DTT ALB 7.535 2.536 4.755 4.7
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 7.751 4.17 6.425 6.282
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 8.873 2.17 2.485 3.322
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 9.79 0.485 3.511 2.07
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serum albumin (ALB) DTT ALB 7.92E-01 -0.07 -0.44
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 5.30E-02 3.89E-01 7.37E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 7.74E-01 -2.06E-02 -1.41E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 5.71E-01 -1.33E-02 -6.44E-02
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021357.
4 Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
5 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.